These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 25506283)

  • 1. Optimizing dendritic cell-based approaches for cancer immunotherapy.
    Datta J; Terhune JH; Lowenfeld L; Cintolo JA; Xu S; Roses RE; Czerniecki BJ
    Yale J Biol Med; 2014 Dec; 87(4):491-518. PubMed ID: 25506283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.
    Datta J; Berk E; Cintolo JA; Xu S; Roses RE; Czerniecki BJ
    Front Immunol; 2015; 6():271. PubMed ID: 26082780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.
    Truxova I; Hensler M; Skapa P; Halaska MJ; Laco J; Ryska A; Spisek R; Fucikova J
    Int Rev Cell Mol Biol; 2017; 330():115-156. PubMed ID: 28215530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
    Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
    Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell immunotherapy.
    Sabado RL; Bhardwaj N
    Ann N Y Acad Sci; 2013 May; 1284():31-45. PubMed ID: 23651191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential approaches for more successful dendritic cell-based immunotherapy.
    Chiang CL; Balint K; Coukos G; Kandalaft LE
    Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
    Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I
    PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic dendritic cell-based cancer vaccines: the state of the art.
    Strioga MM; Felzmann T; Powell DJ; Ostapenko V; Dobrovolskiene NT; Matuskova M; Michalek J; Schijns VE
    Crit Rev Immunol; 2013; 33(6):489-547. PubMed ID: 24266347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
    Versteven M; Van den Bergh JMJ; Marcq E; Smits ELJ; Van Tendeloo VFI; Hobo W; Lion E
    Front Immunol; 2018; 9():394. PubMed ID: 29599770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
    Ramachandran M; Dimberg A; Essand M
    Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.
    Galati D; Zanotta S
    Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
    Wang HY; Wang RF
    Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
    Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
    J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.
    Anguille S; Lion E; Van den Bergh J; Van Acker HH; Willemen Y; Smits EL; Van Tendeloo VF; Berneman ZN
    Hum Vaccin Immunother; 2013 Sep; 9(9):1956-61. PubMed ID: 23778748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer.
    Sutherland SIM; Ju X; Horvath LG; Clark GJ
    Front Immunol; 2021; 12():641307. PubMed ID: 33854509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell gene therapy.
    Onaitis M; Kalady MF; Pruitt S; Tyler DS
    Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer.
    Ragde H; Cavanagh WA; Tjoa BA
    J Urol; 2004 Dec; 172(6 Pt 2):2532-8. PubMed ID: 15538202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
    Shimizu K; Kuriyama H; Kjaergaard J; Lee W; Tanaka H; Shu S
    J Immunother; 2004; 27(4):265-72. PubMed ID: 15235387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.